Expert: Giancarlo Pruneri, National Cancer Institute - IRCCS Foundation, Milan, Italy
Questions:
1-Can You explain what is meant by the title „low positive“ luminal breast cancer?
2-Is that treshold (<10%) uniform everywhere, in the entire oncology /pathology/ community?
3-What are the guidelines to follow on this question?
4-Can You comment on the two tresholds for defining positive HR status (≥1% vs ≥10%)?
5-Is there an implication on therapeutic approach (i.e. how should we be treating these cases, should they receive ET)? Please explain.
